Genta and Aventis Enter Worldwide Collaboration
Agreement for Innovative Apoptosis-Directed Drug for Cancer Treatment
30-Apr-2002 -
Berkeley Heights, NJ and Frankfurt, Germany, April 29, 2002 – Genta Incorporated and Aventis announced today that they have entered into an agreement to jointly develop and commercialize GenasenseTM (G3139), Genta’s lead antisense compound. Genasense is currently in multiple Phase 3 clinical ...
apoptosis
Aventis
cancer therapy
+4